公表論文・ポスター発表資料
PXL770 - AMP Kinase Activators
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, Phase 2a study
Ken Cusi, et al. Lancet Gastroenterol Hepatol — September 2021
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
Pascale Gluais-Dagorn, et al. Hepatol Commun — 2021
Human Proof-of-Concept in NAFLD Patients with PXL770, a Novel First-in-Class Direct AMP-Kinase Activator (mentioné par David)
Ken Cusi et al. — March 2021, NASH-TAG, Oral presentation
Therapeutic efficacy potential of PXL770 - a novel direct AMPK-activator and PXL065 – deuterium-stabilized R-pioglitazone - for X-linked adrenoleukodystrophy
Jaspreet Singh, et al. — November 2020, ALD Connect Annual Meeting
PXL770, a Novel Direct AMP-activated Protein Kinase Activator Produces Greater Efficacy when Combined with Other Key Therapeutic Mechanisms Targeting NASH
Pierre-Axel Monternier, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
PXL770, A New Direct AMP Kinase Activator and Potential NASH Therapeutic, Produces Anti-inflammatory Effects in Mouse Liver and Adipose Tissue and in Human Immune Cells
Pascale Gluais-Dagorn, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
PXL770, a Novel Direct AMP-activated Protein Kinase Activator, Improves Hepatic Mitochondrial Function in a Rodent NASH Model
Pierre-Axel Monternier, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
Chronic Treatment With The Direct AMP Kinase Activator PXL770 Improves Cardiac And Renal Function In Diabetes Related Cardiorenal Syndrome
Y. Stephan et al. — September 2020, EASD (European Association for the Study of Diabetes)
PXL770, a new direct AMP-activated protein Kinase (AMPK) activator, demonstrates anti-inflammatory and anti-fibrogenic effects in DIO-NASH mice model
Pascale Gluais-Dagorn et al. — February 2020, Global NASH Congress, Oral presentation
PXL770, a New Direct AMP Kinase Activator, Acting on the Adipose Tissue and the Liver, Demonstrates Promising Effects for Treatment of Non-Alcoholic Steatohepatitis
Pascale Gluais-Dagorn et al. — November 2018, AASLD (American Association for the Study of Liver Diseases), San Francisco, USA
PXL770, a direct AMPK activator, shows favorable cardiac safety profile
Sophie Hallakou-Bozec et al. — October 2018, International Meeting on AMPK, Toronto, Canada
PXL770, a direct AMPK activator for the treatment of NASH, shows a favorable PK, tolerability and safety profile in humans
Sandrine Perrimond-Dauchy et al. — October 2018, International Meeting on AMPK, Toronto, Canada
PXL770, a new direct AMP Kinase activator, demonstrates promising effects for treatment of non-alcoholic steatohepatitis
Pascale Gluais-Dagorn et al. — February 2018, Global NASH Congress, London, UK
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mouse model of obesity and diabetes EASD,
Sébastian Bolze et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany
PXL770, a Novel Direct AMPK Activator, Inhibits Hepatic de novo Lipogenesis for the Treatment of Metabolic Disorders EASD
Sophie Hallakou-Bozec et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany
PXL770 Demonstrates Therapeutic Potential as a New Direct AMP Kinase Activator WCIRDC
Sophie Hallakou-Bozec et al. — November 2015, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, USA
PXL065 - Deuterium-Stabilized Thiazolidinediones
PXL065 (Deuterium-Stabilized R-enantiomer of pioglitazone) Reduces Liver Fat Content and Improves Liver Histology without PPAR-mediated Side Effects in Patients with NASH: Analysis of a 36 Week Placebo-Controlled Phase 2 Trial (DESTINY-1)
Stephen A. Harrison, et al. — November 2022, AASLD The Liver Meeting
Therapeutic potential of deuterium-stabilized(R)-pioglitazone — PXL065 — for X-linkedadrenoleukodystrophy
Pierre-Axel Monternier, et al. — May 2022, The Journal of Inherited Metabolic Disease (JIMD)
Human Pharmacokinetics and NASH Development Strategy for PXL065 – Deuterium-Stabilized (R)-Pioglitazone
Sebastien Bolze, et al. — March 2021, NASH-TAG
Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
Jacques, V., et al. Hepatol Commun — 2021
Therapeutic efficacy potential of PXL770 - a novel direct AMPK-activator and PXL065 – deuterium-stabilized R-pioglitazone - for X-linked adrenoleukodystrophy
Jaspreet Singh, et al. — November 2020, ALD Connect Annual Meeting
Phase 1b Study of PXL065 (Deuterium-Stabilized R-Pioglitazone), a Novel NASH Candidate, Predicts 15 mg Equivalent to 45 mg Actos®
Sebastien Bolze, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting Racemates
DeWitt, S., et al. ACS Med Chem Lett — 2020
Phase 1 Study of PXL065 Confirms Dose-Proportionality & Stabilization of the Preferred Stereoisomer (R-Pioglitazone) for the Treatment of NASH
Bolze et al. — November 2019, AASLD (American Association for the Study of Liver Diseases), Boston, MA, USA
PXL065, Pioglitazone (pio), and Thiazolidinediones (TZDs): Unraveling Pio’s superior efficacy for NASH and role of stereoisomers
Sheila DeWitt et al. — March 2019, NASH-TAG Oral presentation
Safety, Tolerability & PK of PXL065*, the Stabilized R-Stereoisomer of Pioglitazone: A Mitochondrial Function Modulator for NASH without PPARγ Agonism & Related Side Effects
Vincent Jacques et al. — November 2018, AASLD (American Association for the Study of Liver Diseases), San Francisco, USA
DRX-065: A Novel Mitochondrial Modulator for NASH Pharmacokinetic (PK) Results & Modeling from Phase 1 Study
Vincent Jacques et al. — March 2018, NASH-TAG Poster
DRX-065: A Novel Mitochondrial Modulator
Sheila DeWitt et al. — March 2018, NASH-TAG Oral presentation
The Deuterated (R)-Enantiomer of Pioglitazone as a Nonalcoholic Steatohepatitis (NASH) drug candidate: Results from Diet-Induced Rodent NASH Models and Phase I
Sheila DeWitt et al. — August 2018, ACS (American Chemical Society) Oral presentation
Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine Published as part of the Biochemistry series "Biochemistry to Bedside"
DeWitt, S.H., et al. Biochemistry — 2018
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline-deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
Sharon C. Cheetham et al. — November 2017, AASLD Poster
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline-deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
Sharon C. Cheetham et al. — November 2016, AASLD (American Association for the Study of Liver Diseases), Nottingham, UK
Discovery of DRX-065: Characterizing the non-PPARγ, mitochondrial function modulation and anti-inflammatory activity of thiazolidinedione (TZD) enantiomers using deuterium (MEDI 274)
Anthony W. Czarnik et al. — August 2016, ACS Oral presentation
Imeglimin - Type 2 Diabetes
Efficacy and Safety of Imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
Dubourg, J., et al. Diabetes Obes Metab — 2022
Long-term Safety and Efficacy of Imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial
Dubourg, J., et al. Diabetes Obes Metab — 2021
The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
Vial, G., et al. Endocrinol Diabetes Metab — 2021
Mechanism of Action of Imeglimin: A Novel Therapeutic Agent for Type 2 Diabetes
Hallakou-Bozec, S., et al. Diabetes Obes Metab — 2021
Imeglimin Amplifies Glucose-stimulated Insulin Release From Diabetic Islets Via a Distinct Mechanism of Action
Hallakou-Bozec, S., et al. PLoS One — 2021
Efficacy and Safety of Imeglimin in Japanese Patients with Type 2 Diabetes: A 24-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2b trial
Dubourg, J., et al. Diabetes Obes Metab — 2021
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Dubourg, J., et al. Diabetes Care — 2021
Long-term treatment with imeglimin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes (TIMES 2) (Phase 3)
J. Dubourg et al. — September 2020, EASD (European Association for the Study of Diabetes)
Efficacy And Safety Of Imeglimin In Combination With Insulin In Japanese Patients With Type 2 Diabetes: Results of TIMES 3 Trial (Phase 3)
J. Dubourg et al. — September 2020, EASD (European Association for the Study of Diabetes)
Short-and Long-term Administration of Imeglimin Counters Cardiorenal Dysfunction in a Rat Model of Metabolic Syndrome
Lachaux, M., et al. Endocrinol Diabetes Metab — 2020
Imeglimin Preserves Islet β-cell Mass in Type 2 Diabetic ZDF Rats
Hallakou-Bozec, S., et al. Endocrinol Diabetes Metab — 2020
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects
Fouqueray, P., et al. Clin Pharmacokinet — 2020
Absence of QTc Prolongation in a Thorough QT Study with Imeglimin, a First in Class Oral Agent for Type 2 Diabetes Mellitus
Dubourg, J., et al. Eur J Clin Pharmacol — 2020
In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans
Clemence, C., et al. Drug Metab Dispos — 2020
Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers
Chevalier, C., et al. Eur J Drug Metab Pharmacokinet — 2020
Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
Chevalier, C., et al. Clin Pharmacokinet — 2020
Imeglimin Protects Ins-1 Cells And Human Islets Against High Glucose- And High Fructose-induced Cell Death By Inhibiting The Mitochondrial PTP Opening
Sandrine Lablanche et al. — June 2018, ADA (American Diabetes Association), Orlando, USA
Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial
J. Dubourg — September 2017, EASD (European Association for the Study of Diabetes), Lisbon, Portugal
Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Marianne Lachaux et al. — August 2017, EASD (European Association for the Study of Diabetes), Barcelona, Spain
Imeglimin Opposes Development of Metabolic Syndrome Related Diabetic Cardiomyopathy
Marianne Lachaux et al. — June 2017, ADA (American Diabetes Association), San Diego, USA
Imeglimin Preserves β-cell Function and Mass in Male Zucker Diabetic Fatty Rats World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
Sophie Hallakou-Bozec et al. — December 2016, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, California, USA
Imeglimin Improves Vascular Dysfunction in Type 2 Diabetes Animal Models EASD
Fouqueray P et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany
Imeglimin Improves Insulin Sensitivity in an Adult STZ Rat Model ADA
Sophie Hallakou-Bozec et al. — June 2016, ADA (American Diabetes Association), New Orleans, USA
Imeglimin Increases Insulin Secretion in Response to Glucose as a Unique Mechanism of Action Depending on NAD Synthesis ADA
Sophie Hallakou-Bozec et al. — June 2016, ADA (American Diabetes Association), New Orleans, USA
Imeglimin Lowers Glucose Primarily by Amplifying Glucose-stimulated Insulin Secretion in High-fat-fed Rodents
Perry, R.J., et al. Am J Physiol Endocrinol Metab — 2016
Imeglimin Prevents Human Endothelial Cell Death by Inhibiting Mitochondrial Permeability Transition Without Inhibiting Mitochondrial Respiration
Detaille, D., et al. Cell Death Discov — 2016
Imeglimin, a New Oral Anti-Hyperglycemic Agent Controls Fasting and Post-Prandial Glucose through an Improvement in both Insulin Secretion and Insulin Sensitivity WCIRDC
Fouqueray P et al. — November 2015, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, USA
Dose Ranging-Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes.
Fouqueray P et al. — June 2015, ADA (American Diabetes Association), Boston, USA
Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-fat, High-sucrose Diet Mice Model
Vial, G., et al. Diabetes — 2015
Imeglimin Increases Glucose-dependent Insulin Secretion and Improves Beta-cell Function in Patients with Type 2 Diabetes
Pacini, G., et al. Diabetes Obes Metab — 2015
Imeglimin decreases hepatic glucose production through a unique mitochondrial mechanism of action.
Vial G et al. — June 2014, ADA (American Diabetes Association), San Francisco, USA
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Sitagliptin Monotherapy
Fouqueray, P., et al. Diabetes Care — 2014
Imeglimin: A new antidiabetic agent that provides added benefit to DPP-4 inhibitor therapy.
Fouqueray P et al. — June 2013, ADA (American Diabetes Association), Chicago, USA
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
Fouqueray, P., et al. Diabetes Care — 2013
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy
Fouqueray P et al. — June 2012, ADA (American Diabetes Association), Philadelphia, USA
The effects of the antidiabetic Imeglimin in hyperglycemic mice with septic shock.
Wagner F et al. — March 2012, ISICEM (International Symposium on Intensive), Brussels, Belgium
Imeglimin, A Novel Glimin Oral Antidiabetic, Exhibits a Good Efficacy and Safety Profile in Type 2 Diabetic Patients
Pirags, V., et al. Diabetes Obes Metab — 2012
Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes
Fouqueray, P., et al. Journal of Diabetes & Metabolism — 2011
Imeglimin, a novel glimin oral anti-diabetic, exhibits good glycemic control in type 2 diabetic patients.
Pirags V et al. — September 2010, EASD (European Association for the Study of Diabetes), Stockholm, Sweden